SITE005-0047

SITE005 (FRA) › SITE005-0047

SITE005-0047

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2025-10-25

enrolled

AEs

3

Serious

2

Dropout signal

–

Adverse events

3

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-02-17 (study day 289); relationship: NOT RELATED

moderate assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-05 (study day 62); relationship: NOT RELATED; serious criteria: hospitalization

severe serious assessed

Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-06-06 (study day 33); relationship: NOT RELATED; serious criteria: hospitalization

severe serious assessed

Data queries

0

No data queries. Open queries would appear here for this patient.